Drugs / Interferon-β
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00811395 Background | Oct 2007 → Apr 2010 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT06663189 Comparator | Jan 2025 → Jan 2027 expected | relapsing-remitting multiple sclerosis | University Hospital, Strasbourg, France | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon-β | “Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate” NCT06663189 ↗ |
| Known as | IFN-β | “Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate” NCT06663189 ↗1“Interferon-β [IFN-β]” NCT00811395 ↗ |
| Route | Intramuscular | “Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection” NCT00811395 ↗ |
| Route | Subcutaneous | “Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection” NCT00811395 ↗ |